I
Ian D. Pavord
Researcher at University of Oxford
Publications - 654
Citations - 55329
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 108, co-authored 575 publications receiving 47691 citations. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Papers
More filters
Journal ArticleDOI
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D. Pavord,Stephanie Korn,Peter H. Howarth,Eugene R. Bleecker,Roland Buhl,Oliver N. Keene,Hector Ortega,Pascal Chanez +7 more
TL;DR: Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma.
Journal ArticleDOI
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector Ortega,Mark C. Liu,Ian D. Pavord,Guy Brusselle,J. Mark FitzGerald,Alfredo Chetta,Marc Humbert,Lynn Katz,Oliver N. Keene,Steven W. Yancey,Pascal Chanez +10 more
TL;DR: Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control and the safety profile of mepolIZumab was similar to that of placebo.
Journal ArticleDOI
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar,Christopher E. Brightling,Beverley Hargadon,Sunil Gupta,W Monteiro,Ana R. Sousa,Richard P. Marshall,Peter Bradding,Ruth H. Green,Andrew J. Wardlaw,Ian D. Pavord +10 more
TL;DR: The results of this study suggest that eosinophils have a role as important effector cells in the pathogenesis of severe exacerbations of asthma in this patient population.
Journal ArticleDOI
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
Ruth H. Green,Christopher E. Brightling,S McKenna,Beverley Hargadon,Debbie Parker,Peter Bradding,Andrew J. Wardlaw,Ian D. Pavord +7 more
TL;DR: A treatment strategy directed at normalisation of the induced sputum eosinophil count reduces asthma exacerbations and admissions without the need for additional anti-inflammatory treatment.
Journal ArticleDOI
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
Helen K. Reddel,D. Robin Taylor,Eric D. Bateman,Louis-Philippe Boulet,Homer A. Boushey,William W. Busse,Thomas B. Casale,Pascal Chanez,Paul L. Enright,Peter G. Gibson,Johan C. de Jongste,Huib A. M. Kerstjens,Stephen C. Lazarus,Mark L Levy,Paul M. O'Byrne,Martyn R Partridge,Ian D. Pavord,Malcolm R. Sears,Peter J. Sterk,Stuart W. Stoloff,Sean D. Sullivan,Stanley J. Szefler,Mike Thomas,Sally E. Wenzel +23 more
TL;DR: New definitions for asthma control, severity, and exacerbations are developed, based on current treatment principles and clinical and research relevance, to provide a basis for a multicomponent assessment of asthma by clinicians, researchers, and other relevant groups in the design, conduct, and evaluation of clinical trials, and in clinical practice.